Our mission is to capitalize on advanced molecular pharmacology and high efficiency CBD
delivery systems activating CB receptors for human endocannabinoid system therapeutics.
The team at CBD Medical Network, Inc. a wholly owned subsidiary of EndoStat Therapies, has assembled a team of seasoned C-level business professionals with relevant diverse skills. CBD Med Net is the inspiration of Neuroscientist Leslie Terry PhD. with specialized skills in Psychopharmacology, Statistical Analysis, Autoradiography (2-DG & receptor), Behavioral Analysis, Receptor Analysis, Experimental Design, HPLC, Lab Management, Neuroanatomical Analysis and Neurochemical Analysis. The focus of her team lies in quantifying the growing body of evidence as it relates to affecting the Endocannabinoid Receptor System
CBD Med Net is working with EST to create/design/improve effective, safe and reliable delivery systems that best provide the highest bioavailability and uncompromised quality. To that end a nationally recognized Hospital and University has agreed to submit an FDA application to conduct a clinical trial using CBD as an adjunct or possibly replacement for opiates in pain management for post operative surgeries – employing the NaturDose inhaler. Other US university hospitals to conduct clinical trials for different applications are standing by.
The Hemp Business Journal estimates that the CBD market will grow to $2.1 billion in US consumer sales by 2020 with $450 million being from hemp-based sources.
Our business model is simple - Tom Clancy once said, “reading is elementary.” Unfortunately, the trove of CBD research information available on the Internet is either unsubstantiated or far too complex for the average reader and there is much confusion and misconception. The CBD Med Net research team is identifying and collecting peer reviewed validated published journal articles and creating a repository of clinically relevant data to share with the scientific community and consumers alike. We leverage our focused scientific research to build industry contacts and to offer consumers a reliable and highly respected brand through EndoStat Therapies.
Our business strategy will evolve – The Companies’ culture is focused on the health and well being potentially offered from hemp oil sourced CBD as a product. Currently in research infancy, only two Cannabinoid receptors (CB1 & CB2) have been identified. Comparably, only 2 opiate receptors were identified in the 70’s. Decades of research now reveal over 14 indigenous receptors allowing for the identification of precise targeting and understanding of a wide range of pain management, psychiatric and physiological applications. CBD Med Net will be steadfast in bringing the world of molecular pharmacology, leveraging high quality published research, to identify and extrapolate newly identified CB compounds to more precisely target critical areas of medicine. Through enhancing delivery systems and expanding innovative compounds, we envision the future of this work to provide a better quality of life to all.
Our Key Success Factors will include –The companies’ ability to attract like-minded scientists, building a repository and access to cutting-edge research, translate the discovery of compounds/receptors and partner with business leaders will prove to contribute to the health care revolution. Our goal is to develop first-to-market dispensing formulas and products, while collaborating with business and scientific leaders through a proven project management framework and continued innovation into new areas.
Produced By CBD LUXE.
